1. The Role of Carcinoembriogenic Antigen in Predicting Response and Survival to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer
- Author
-
Angelita Habr-Gama, Rodrigo Oliva Perez, Igor Proscurshim, Fábio Campos, Guilherme Pagin São Julião, Joaquim Gama-Rodrigues, Desidério Roberto Kiss, and Ivan Cecconello
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Stage (cooking) ,Radical surgery ,neoplasms ,Neoadjuvant therapy ,Neoplasm Staging ,Retrospective Studies ,Tumor marker ,Chi-Square Distribution ,Rectal Neoplasms ,business.industry ,Gastroenterology ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Primary tumor ,Neoadjuvant Therapy ,digestive system diseases ,Carcinoembryonic Antigen ,Surgery ,Survival Rate ,Treatment Outcome ,Chemotherapy, Adjuvant ,Female ,Radiotherapy, Adjuvant ,business ,Chemoradiotherapy - Abstract
PURPOSE: Carcinoembriogenic antigen (CEA) is the most frequently used tumor marker in rectal cancer. A decrease in carcinoembriogenic antigen after radical surgery is associated with survival in these patients. Neoadjuvant chemoradiotherapy may lead to significant primary tumor downstaging, including complete tumor regression in selected patients. Therefore, we hypothesized that a decrease in CEA after neoadjuvant chemoradiotherapy could reflect tumor response to chemoradiotherapy, affecting final disease stage and ultimately survival. METHODS: Patients with distal rectal cancer managed by neoadjuvant chemoradiotherapy and available pretreatment and postchemoradiotherapy levels of CEA were eligible for the study. Outcomes studied included final disease stage, relapse, and survival, and these were compared according to initial CEA level, postchemoradiotherapy CEA level, and the reduction in CEA. RESULTS: Overall 170 patients were included. Postchemoradiotherapy CEA levels
- Published
- 2009
- Full Text
- View/download PDF